IXICO PLC (LON:IXI) said it will provide data analytics and neuroimaging services to a late-stage programme for people with the degenerative brain disorder Huntington's disease.
Its expertise will be used in what’s called an extension study to allow people living with Huntington's to continue to contribute to the search for a treatment for the condition. IXICO’s involvement will generate a further £500,000 in revenues.
WATCH: IXICO to support late phase clinical research programme in Huntington's disease
“The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development," said chief executive Giulio Cerroni.
In a note to clients, analysts at ‘house’ broker Shore Capital commented: “The extension is further evidence of IXICO’s momentum in Huntington’s disease, having agreed four new contracts for the condition in its last financial year, including a £9.1mln agreement for a pivotal Phase III trial announced in September.”
In afternoon trading, IXICO shares eased back after hitting an early session high of 32p, losing a penny at 29.50p.
-- Adds analyst comment, share price --